Ruzurgi (amifampridine, base form) is an oral drug intended for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in children aged 6 to < 17 years. Ruzurgi is a voltage-gated potassium channel inhibitor that prolongs the depolarization of the pre-synaptic cell membrane, allowing for enhanced calcium influx into the neuron. This facilitates increased release of acetylcholine and improves neuromuscular transmission.
If you have a Hayes login, click here to view the full report on the Knowledge Center.